Anti-Rat IL-5

Purified Recombinant Rat IL5 (>98%)

This antigen affinity purified polyclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco’s phosphate buffered saline (1X PBS) pH 7.2 – 7.3 containing 5.0% w/v trehalose with no calcium, magnesium, or preservatives present.

Lyophilized

The lyophilized antigen affinity purified polyclonal antibody can be stored desiccated at 20°C to 70°C for twelve months from date of receipt. The reconstituted antibody can be stored for at least four weeks at 28°C. For longterm storage of the reconstituted antibody, aseptically aliquot into working volumes and store at 20°C to 70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. No detectable loss of activity was observed after six months.

Next Day Ambient

Immunohistochemistry on Frozen Sections: This antibody should give satisfactory staining results when used on frozen sections at a concentration of 15 µg/ml.
Neutralization: This antibody is useful for neutralization of Rat IL5 bioactivity. The antibody dose required to neutralize 50% (ND₅₀) of the biological activity of Rat IL5 (at 1.25 ng/ml) is 26 µg/ml.

Goat AntiRat Interleukin 5 (IL5) recognizes Rat IL5. This antigen affinity purified polyclonal antibody was purified using a proprietary chromatographic technique that includes covalently immobilizing the antigen proteins or peptides to agarose based beads. This purification method enhances specificity, reduces nonspecific binding of extraneous IgG and provides you with the most reliable reagent available for your early discovery research.

IL5 is a 26 kD TH2 cytokine and a homodimeric glycoprotein that is part of the hematopoietic family. IL5 stimulates B cell growth as well as increases Ig secretion. It is the main factor that promotes the terminal differentiation of eosinophil progenitors and enhances the effector capacity of mature eosinophils. IL5 is a major regulator of eosinophil accumulation in tissues. In fact, in Hodgkin lymphoma, the characteristically observed eosinophilia is suspected to result from an increased production of IL5. IL5 may also be the cause of several allergic diseases including asthma, where it is thought that eosinophils have a significant role in the disease pathology. There are several mAbs currently in use that target IL5 for the treatment of severe eosinophilic asthma.